Salute e Benessere

Press Release: Dupixent approved as the first-ever biologic medicine in Japan…

Dupixent approved as the first-ever biologic medicine in Japan for patients with COPDFollowing recent approvals in the EU, China, and the US, this approval was based on pivotal phase 3 results in adults with elevated eosinophilsApproval marks the first new treatment approach for COPD in more than a decade in Japan and the sixth approved indication for chronic diseases with underlying type 2 inflammationParis and Tarrytown, NY, March 28, 2025.The Ministry of Health, Labour and...
Nasdaq GlobeNewswire
28/03/2025

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to…

DBV Technologies Announces Financing of up to $306.9 Million (€284.5 Million) to Advance Viaskin® Peanut Patch Through Biologics License Application Submission and U.S. Commercial Launch, if Approved DBV secures $125.5 million (€116.3 million) up front and up to $181.4 million (€168.2 million), subject to the full exercise of warrantsDBV sufficiently funded through the expected Biologics License Application (BLA) submission to Food and Drug Administration (FDA) for the Viaskin®...
Nasdaq GlobeNewswire
28/03/2025

Shanton Reveals Topline Data from Phase 2b Study in Refractory Gout Patients

"We are excited and very pleased with the outcome of our Phase 2b clinical study in this difficult-to-treat population of refractory gout patients" says Dr. Bing Li, Shanton's CEO. "By the end of month 3 in our study, nearly 100% of patients that were confirmed exposed to daily SAP-001 30 and 60 mg dosages on top of conventional therapy reached the study's therapeutical target (serum uric acid levels below 6mg/dL), compared to only about 10% of patients on conventional treatment…
PR Newswire
28/03/2025

The Interleukin-2 Market is Set to Reach USD 4 Billion by 2034, Driven by IL-2…

Key Highlights Key Highlights Learn more about the IL-2 treatment landscape @Interleukin-2 Therapeutic Landscape In the years that followed, PROLEUKIN's approval extended to metastatic melanoma in 1998, another challenging cancer to treat. However, despite its revolutionary impact, high-dose IL-2 therapy posed significant obstacles, including severe toxicity, systemic inflammatory responses, and a short half-life. These drawbacks spurred efforts to refine its clinical use,...
PR Newswire
27/03/2025

Teva to Host Conference Call to Discuss First Quarter 2025 Financial Results at…

In order to participate, please register in advance here to obtain a local or toll-free phone number and your personal pin.A live webcast of the call will be available on Teva's website at: https://ir.tevapharm.com/Events-and-Presentations .Following the conclusion of the call, a replay of the webcast will be available within 24 hours on Teva's website. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical leader,...
Nasdaq GlobeNewswire
27/03/2025

Teva Releases Q1 2025 Aide Memoire

Q1 2025 Aide Memoire Teva has prepared this document to assist in the financial modeling of its quarterly results. The document is based on Teva's prior results, management's previous commentary about Teva's business outlook and data from select independent sources. Going forward, it is Teva's intention to provide this information towards the end of each quarter. About Teva Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) is a different kind of global biopharmaceutical...
Nasdaq GlobeNewswire
27/03/2025

Nanobiotix Announces First Data From the Completed Dose Escalation Part of a…

Data show favorable safety and confirm injection feasibility in 12 patients with locally advanced NSCLC amenable to re-irradiation for whom prior lines of therapy have failedA preliminary review of survival data showed 12-month LPFS of 64% (median 18.6 months) and 12-month OS of 83% (median 30.2 months)The dose escalation part is complete, and 5/12 patients have been injected to date in the ongoing expansion part PARIS and CAMBRIDGE, Mass., March27, 2025(GLOBE NEWSWIRE) --...
Nasdaq GlobeNewswire
27/03/2025

Galapagos Publishes 2024 Annual Report and Announces Annual Shareholders'…

Mechelen, Belgium; March 27, 2025, 21:01 CET; regulated information – Galapagos NV (Euronext & NASDAQ: GLPG) today publishes its annual report for the financial year 2024 and announces its Annual Shareholders' Meeting (AGM) to be held on Tuesday, April 29, 2025 at 14:00 CET at the registered office of the Company. The annual report for the financial year 2024, including a review of figures and performance, is available online athttps://www.glpg.com/financial-reportsand can also be...
Nasdaq GlobeNewswire
27/03/2025

TraceLink Secures Top Honors with BSMA Supply Chain Excellence Award for…

"We're honored that BSMA recognizes the unique journey TraceLink is embarked on to help transform the industry's ability to serve patients globally," said Shabbir Dahod, President and CEO of TraceLink. "For many companies, mandated track-and-trace and compliance requirements were the first step in their digital supply chain journey. MINT builds on that foundation, turning compliance, quality, and patient safety into a strategic advantage. End-to-end digitalization and the ability…
PR Newswire
27/03/2025

AAHRPP Accredits Two More International Organizations, Including the First in…

"Each accreditation brings us closer to shared global standards for conducting research and protecting research participants," AAHRPP President and CEO Elyse I. Summers said. "We applaud our accredited organizations for their vital role in strengthening the research enterprise and advancing discoveries that benefit all of us." "Each accreditation brings us closer to shared global standards for conducting research and protecting research participants," AAHRPP…
PR Newswire
27/03/2025

Resolutions from Zealand Pharma's Annual General Meeting 2025

Company announcement – No. 7 / 2025 Resolutions from Zealand Pharma's Annual General Meeting 2025Copenhagen, Denmark, March 27, 2025 -Zealand Pharma A/S ("Zealand") (Nasdaq: ZEAL) (CVR-no. 20045078), a biotechnology company focused on the discovery and development of innovative peptide-based medicines, today held its Annual General Meeting of 2025 as a partly electronic and partly physical general meeting (hybrid meeting). At the Annual General Meeting, all proposals presented to...
Nasdaq GlobeNewswire
27/03/2025

Essity's 2025 Annual General Meeting

The meeting resolved on a dividend for the financial year 2024 of SEK 8.25 per share. Record date for the dividend is set to Monday, March 31, 2025. The dividend is expected to be distributed by Euroclear Sweden AB on Thursday, April 3, 2025. The meeting resolved on a dividend for the financial year 2024 ofSEK 8.25per share. Record date for the dividend is set toMonday, March 31, 2025. The dividend is expected to be distributed by Euroclear Sweden AB onThursday, April 3, 2025...
PR Newswire
27/03/2025

ERS Genomics and Jumpcode Genomics sign CRISPR/Cas9 license agreement

Mike Salter, President & CEO of Jumpcode Genomics, commented: "At Jumpcode, we are revolutionizing the field of genomics by harnessing the power of CRISPR technology to enhance the sensitivity and efficiency of next-generation sequencing. Our strategic partnership with ERS Genomics, granting us access to their foundational CRISPR/Cas9 IP portfolio, further empowers us to develop innovative solutions across multiple applications. By combining this foundational IP with our own robust…
PR Newswire
27/03/2025

Urteste plans to start clinical trials for its pancreatic cancer test in Europe…

27 MARCH 2025 PRESS RELEASE Urteste plans to start clinical trials for its pancreatic cancer test in Europe in Q3 2025Gdańsk, Poland – 27 March 2025 – Urteste S.A. (Warsaw Stock Exchange: URT), a company specializing in innovative technology for cancer detection through unique urine sample analysis, plans to initiate clinical trials in the European Union in Q3 2025 for the Panuri project—a diagnostic test for pancreatic cancer. In the coming weeks, Urteste will announce a...
Nasdaq GlobeNewswire
27/03/2025

Resolutions from the Annual General Meeting of Novo Nordisk A/S

Bagsværd, Denmark, 27 March 2025 - Today, Novo Nordisk A/S held its Annual General Meeting.At the Annual General Meeting, Helge Lund, chair of the Board of Directors communicated: “2024 was another year of significant growth for Novo Nordisk, characterised by continued innovation, capacity expansions and commercial execution. Our industry-leading therapeutic innovations benefited more than 45 million people living with diabetes and obesity worldwide. As we strive to keep pace with...
Nasdaq GlobeNewswire
27/03/2025

Single-cell Analysis Market Surges to USD 5.4 Billion by 2033, Propelled by 9.5%…

Download PDF Brochure: https://www.verifiedmarketreports.com/download-sample/?rid=480559 Download PDF Brochure:https://www.verifiedmarketreports.com/download-sample/?rid=480559 Browse in-depth TOC on Single-cell Analysis Market 202 - Pages 126 – Tables 37 – Figures Scope of The Report Global Single-cell Analysis Market Overview Key Market Drivers Fueling Growth in the Single-cell Analysis Market To Purchase a Comprehensive Report Analysis:...
PR Newswire
27/03/2025

Smart Pills Market worth US$1.30 billion by 2030 with 11.2% CAGR |…

Browse in-depth TOC on "Smart Pills Market" Browse in-depth TOC on "Smart Pills Market" 140 - Tables 33 - Figures 150 - Pages By application,smart pills market is bifurcated into capsule endoscopy, patient monitoring, and targeted drug delivery. In 2023, patient monitoring segment accounted for the second largest share of smart pills market. This is attributed to launch of innovative sensor technologies and the rising need for precise & accurate measurement of inner...
PR Newswire
27/03/2025

Bearings Market Surges to USD 241.62 Billion by 2033, Propelled by 4.9% CAGR -…

Download PDF Brochure:https://www.verifiedmarketreports.com/download-sample/?rid=113682 Browse in-depth TOC on Bearings Market 202 - Pages 126 – Tables 37 – Figures Scope of The Report Global Bearings Market Overview Key Market Drivers Fueling Growth in the Bearings Market 1. Expanding Industrial Automation and Robotics The surge in industrial automation is a primary force accelerating the bearings market. With manufacturing...
PR Newswire
27/03/2025

Zelluna ASA [ZLNA]: Key information regarding reverse share split and change of…

Reference is made to the stock exchange notice published on 9 January 2025 regarding an extraordinary general meeting held in Zelluna ASA (the " Company "), where it was resolved to carry out a reverse share split in the ratio 10:1. Radforsk Investeringsstiftelse has further agreed with the Company to make available, without any compensation a, necessary number of its existing shares to the Company to ensure that all fractions of shares are rounded up to the nearest whole share…
Nasdaq GlobeNewswire
27/03/2025

TOOsonix Partners with Consultronix to Introduce its Innovative Dermatological…

TOOsonix's MDR CE-marked dermatological therapy addresses a wide range of age-related skin diseases, including very common basal cell carcinoma, actinic keratosis, and seborrheic keratosis. Treatments are fast, non-invasive, without need for anesthesia or post treatment, and have higher efficacy and better aesthetic outcome than traditional procedures. TOOsonix's MDR CE-marked dermatological therapy addresses a wide range of age-related skin diseases, including very common basal cell…
PR Newswire
27/03/2025

Abbott Receives CE Mark for its Volt™ Pulsed Field Ablation System to Treat…

CE Mark approval for the Volt PFA System was granted based on strong results from Abbott's Volt CE Mark study, a global clinical trial conducted at centers in Europe and Australia. The trial showed the Volt PFA System achieved pulmonary vein isolation (PVI) – the method of destroying tissue causing a patient's AFib – in 99.1% of veins during ablation procedures with far fewer energy applications than on-market competitive PFA systems.3 CE Mark approval for the Volt PFA System was granted…
PR Newswire
27/03/2025

Evaxion to announce business update and full year 2024 financial results on…

COPENHAGEN, Denmark, March 27, 2025 - Evaxion Biotech A/S (NASDAQ: EVAX) (“Evaxion”), a clinical-stage TechBio company specializing in developing AI-Immunology™ powered vaccines, will provide a business update and report its full year 2024 financial results on Tuesday April 1, 2025, before opening of the Nasdaq CM.Evaxion's Executive Management will host a conference call and webcast the same day at 14:30 CET/08:30 EST, presenting the update and results as well as taking questions...
Nasdaq GlobeNewswire
27/03/2025

TIVDAK® (tisotumab vedotin) Approved by Japan Ministry of Health, Labour and…

Media ReleaseCOPENHAGEN, Denmark; March 27, 2025 TIVDAK ®is the first and only antibody-drug conjugate (ADC) approved for patients with advanced or recurrent cervical cancer in JapanApproval is based on results from the global Phase 3 innovaTV 301 trial, in which TIVDAK demonstrated superior overall survival compared to chemotherapyRising cervical cancer incidence and mortality rates in Japan signify need for new treatment optionsGenmab A/S(Nasdaq:GMAB)...
Nasdaq GlobeNewswire
27/03/2025

Gergely Sved appointed CEO of Ellab

Prior to Ecolab, Mr Sved spent 23 years with General Electric in various roles, including most recently at GE Healthcare, where for six years he was Vice President and General Manager Europe Services. Prior to Ecolab, Mr Sved spent 23 years with General Electric in various roles, including most recently at GE Healthcare, where for six years he was Vice President and General Manager Europe Services. Anders Hedegaard, Chair of Ellab, commented: "Ellab is at a very exciting point in time as...
PR Newswire
27/03/2025
Altri  Comunicati